Case report

An unusual case of *Salmonella* Enteritidis causing pneumonia, septic shock and multiple organ failure in an immunocompetent patient

M.L. Thompson Bastin\(^a,b,*\), N.R. Neville\(^b\), R.E. Parsons\(^b\), A.H. Flannery\(^a,b\), S.J. Tennant\(^a\), C.A. Johnson\(^c\)

\(^a\) University of Kentucky HealthCare, Department of Pharmacy Services, 800 Rose Street H110, Lexington, KY 40536, USA
\(^b\) University of Kentucky College of Pharmacy, Department of Pharmacy Practice and Science, 800 Rose Street H110 Lexington, KY 40536, USA
\(^c\) University of Kentucky College of Medicine, Division of Pulmonary, Critical Care and Sleep Medicine, 800 Rose Street H110 Lexington, KY 40536, USA

A R T I C L E   I N F O

Article history:
Received 26 August 2016
Received in revised form 11 October 2016
Accepted 14 October 2016
Available online xxx

Keywords:
*Salmonella* Enteritidis
Pneumonia
Septic shock
Immunocompetent

A B S T R A C T

Salmonella species are facultative intracellular pathogens that most frequently cause self-limiting gastrointestinal disease, often acquired through the ingestion of contaminated food. We report the case of a 33-year-old otherwise healthy, not overtly immunosuppressed, man who was transferred to our facility with the chief complaint of respiratory failure and septic shock. Computed tomography of the chest revealed multifocal pneumonia in both lungs. A bronchial alveolar lavage was performed in the right middle lobe and cultures predominantly grew *Salmonella enterica* serovar Enteritidis. The patient received a prolonged course of antimicrobials, ultimately changing to oral levofloxacin. The etiology of the salmonella infection likely occurred through an aspiration event. Salmonella species are not a typical respiratory pathogen in immunocompetent hosts; however, clinicians should be aware of the possibility that salmonella species may be a pathogenic source of infection in the lungs; a prolonged course of antimicrobials may be warranted.

\(^*\) 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).

Introduction

Salmonellosis may present with varying clinical infections from gastroenteritis to enteric fever [1]. According to the Centers for Disease Control and Prevention (CDC), salmonellosis is estimated to cause one million cases of illness in the United States, with 19,000 hospitalizations and 380 deaths annually [2]. Pneumonia, however, is an atypical site for salmonellosis. Most individuals infected with the bacterium develop fever, abdominal cramps, and diarrhea between 12 and 72 h after infection. The illness manifests as gastrointestinal distress and generally lasts 4–7 days; however, more severe infections can invade into the blood stream and cause bacteremia with the possibility of disseminated focal infection. The severity and risk of translocation are often determined by the virulence of the isolate and host immunity [1]. In severe cases patients are at risk of death if not promptly treated with antimicrobials. Infants, elderly, and individuals who are immunocompromised are more likely to present with severe illness from salmonellosis [2].

Case report

A 33-year-old white male with an intellectual disability residing in a community group home was admitted to an outside hospital with nausea, vomiting, and diarrhea and was found to be hypotensive with acute kidney injury (AKI) and a serum creatinine of 5 mg/dL. Past medical history was significant for hypertension, schizophrenia, depression, anxiety, and seizures. The patient’s medication history directly from the patient’s group included metoprolol tartrate, mirtazapine, prazosin, sertraline, cyproheptadine, vitamin D supplement, multivitamin, divalproex sodium, quetiapine and pantoprazole. At the time of admission he was not known to have any medication allergies, except a possible intolerance to phenytoin.

While at the outside hospital, his respiratory status quickly declined requiring emergent intubation and transfer to the ICU. A computed tomography (CT) of his abdomen revealed diffuse edema in the rectum, colon, and small bowel, as well as vasoconstriction of the mesenteric arteries. Due to the patient’s elevated lactate of 6 mmol/L an exploratory laparotomy was

http://dx.doi.org/10.1016/j.idcr.2016.10.004
2214-2509 © 2016 The Authors. Published by Elsevier Ltd. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
performed with no significant findings. The patient was started on intravenous linezolid, meropenem and metronidazole prior to transfer due to septic shock with suspected abdominal or pulmonary source. In addition, he underwent hemodialysis prior to transfer due to oliguric AKI with severe metabolic acidosis.

Two days after initial admission, the patient arrived at our facility and was found to be febrile, hypotensive with septic shock and multiple organ failure. Maximum recorded temperature on admission was 102.2°F. The patient had a leukocytosis with a white blood cell count of 18.2 k/ul (normal range 3.7–10.3 k/ul) comprised of: neutrophils 81% (normal range 34–71%), lymphocytes 7%, (normal range 20–55%), and eosinophils 0% (normal range 1–7%). The immature granulocyte count was 2%, (normal range 0–1%). Renal function tests were found to be abnormal with serum creatinine 2.59 mg/dL (normal range 0.80–1.3 mg/dL) and blood urea nitrogen 23 mg/dL (normal range 7–21 mg/dL). Liver function tests were also abnormal with aspartate aminotransferase (AST) elevated at 704 U/L (normal 11–41 U/L), alkaline phosphatase normal at 79 U/L (normal 40–115 U/L) and total bilirubin 0.4 mg/dL (normal 0.2–1.1 mg/dL). The patient’s initial lactate level at our facility was elevated at 9.5 mmol/L, which was increased from the documented lactate at the outside hospital and the arterial pH was measured at 7.07. A procalcitonin level was substantially elevated at 157.8 ng/mL. His hypotension persisted with a mean arterial pressure (MAP) 62, on norepinephrine and phenylephrine infusions. He was also found to have rhabdomyolysis with a creatinine kinase of >20,000 U/L (normal 52–336 U/L). The patient had a partial pressure of oxygen to fraction of inspired oxygen (Pao2/FiO2) ratio of 71 on 100% oxygen.

Upon admission, the patient was also begun on continuous renal replacement therapy for treatment his acute oliguric renal failure and metabolic acidosis. He was continued on broad-spectrum empiric antimicrobials that included vancomycin, cefepime, metronidazole, and micafungin for possible pneumonia or abdominal source. A urinalysis was unremarkable. The patient was noted to have altered mental status, for which the differential diagnosis included possible seizures considering the patient’s PMH, potential anoxic brain injury due to the respiratory arrest. A serum valproic acid level was drawn to assess possible toxicity and returned at 4 μg/mL (normal therapeutic range 50–100 μg/mL). CT of the head was negative for any acute changes. Intravenous acyclovir was added to the patient’s empiric antimicrobial regimen on day 2 for possible viral encephalitis. Due to the severity of the patient’s illness and reported hobbies of fishing and outdoor stream and river exposure, doxycycline was empirically added for possible tick-borne disease. Both acyclovir and doxycycline were discontinued after 2 days of therapy and no change in clinical status. A two-dimensional transthoracic echocardiogram was completed with no significant findings. Blood and urine cultures were negative.

On day 1 of the patient’s hospital course at our institution, the patient had a severe pneumonia with elevated WBC, purulent tracheal secretions, PaO2/FiO2 71, and chest radiograph indicating very low lung volumes with significant atelectasis. CT of the chest was performed on day 2 and revealed multifocal bilateral pneumonia. Subsequent bronchoscopy identified mucus plugs in the right middle lobe, right lower lobe, and left lower lobe and a bronchial alveolar lavage (BAL) was done on the right middle lobe. A potassium hydroxide preparation was performed on the BAL specimen and revealed no fungal elements; micafungin was discontinued after 4 days of therapy. A Gram stain was performed on the BAL specimen and revealed rare epithelial cells, rare white blood cells and no micro-organisms. An acid fast bacterium stains on the BAL fluid and subsequent AFB culture was negative. On day 5 the culture from the BAL predominantly revealed a non-lactose fermenting Gram negative rod as well as some K. pneumoniae. The antimicrobial regimen was narrowed to cefepime plus a single dose of tobramycin while awaiting susceptibilities of the Gram-negative pathogen. At this time, the chest radiograph indicated persistent but improving right upper lobe airspace disease with mild worsening patchy left lung airspace disease. The non-lactose fermenting Gram-negative bacillus was identified as a salmonella and reference laboratory speciation found it to be Salmonella enterica serovar Enteritidis (S. Enteritidis).

Empiric antimicrobials were de-escalated on day 6 based on the results of susceptibility testing (Table 1). In total, the patient received 6 days of parenteral cefepime followed by 10 days of oral levofloxacin. It should be noted that according to the final susceptibility results of both the K. pneumoniae and S. Enteritidis

---

**Table 1**

Antimicrobial Minimum Inhibitory Concentration results for S. Enteritidis and K. Pneumoniae recovered via Bronchial Alveolar Lavage Culture.

| Pathogen                     | Antibiotic                  | Minimum Inhibitory Concentration (mcg/ml)* |
|------------------------------|-----------------------------|-------------------------------------------|
| **90% Salmonella Enteritidis** | Ampicillin                  | >36 Resistant                              |
|                              | Trimethoprim/Sulfamethoxazole | ≤0.5/9.5 Susceptible                       |
|                              | Ceftriaxone                  | 0.047 (ETEST)                              |
|                              | Levofloxacin                 | ≤1 No CLSI Range                           |
| **10% Klebsiella Pneumoniae** | Amikacin                    | ≤8 Susceptible                             |
|                              | Ampicillin                   | ≥16 Resistant                               |
|                              | Ampicillin/Sulbactam         | 8/4 Susceptible                            |
|                              | Aztreonam                    | ≤2 Susceptible                             |
|                              | Cefazolin                    | ≤2 Susceptible                             |
|                              | Cefepime                     | ≤1 Susceptible                             |
|                              | Cefoxime                     | ≤4 Susceptible                             |
|                              | Gentamicin                   | ≤2 Susceptible                             |
|                              | Levofloxacin                 | ≤1 Susceptible                             |
|                              | Meropenem                    | ≤1 Susceptible                             |
|                              | Piperacillin/Tazobactam      | 4/4 Susceptible                            |
|                              | Tetracycline                 | ≤2 Susceptible                             |
|                              | Tobramycin                   | ≤2 Susceptible                             |
|                              | Trimethoprim/Sulfamethoxazole | ≤0.5/9.5 Susceptible                      |
|                              | Tetracycline                 | ≤0.5 Susceptible                           |

* Susceptibility testing and isolate identification performed by BD PhoenixTM Automated Microbiology System.
found on the BAL, both were susceptible to cefepime. The patient was treated with cefepime for a total of 6 days prior to the de-escalation to levofloxacin. By the final day of antimicrobials, the patient was afebrile, his WBC had decreased to 13.6k/µL and was tolerating ventilation through a tracheostomy prior to weaning from the ventilator. Follow up respiratory cultures did not grow any salmonellae. No stool cultures were initially obtained and later stool cultures as well as stool comprehensive PCR testing did not show evidence of salmonellae or any other pathogens. The patient was transferred on day 28 to a long-term acute care rehabilitation facility. At the time of discharge the patient was afebrile, stable on room air, tolerating a speech valve through his tracheostomy stating that he felt well.

**Discussion**

Non-typhoid salmonellae (NTS) are present in industrialized nations and are associated with contaminated food products [3]. NTS infects and colonizes a wide range of animal hosts and human disease generally manifests as self-limiting gastroenteritis. Salmonella are acid susceptible and must survive the gastric acid barrier and traverse a mucosal barrier before invading intestinal epithelial cells [1]. Previous gastric surgery and medications that reduce gastric acidity increase susceptibility to NTS infection [4]. Once the bacterium has evaded the gastric acid and mucosal barriers, it invades intestinal epithelial cells through a process called bacteria-mediated endocytosis [5]. The innate immune system is activated by multiple pro-inflammatory pathways including activation of toll-like receptor (TLR)-4 in the presence of lipopolysaccharide on the cell surface, TLR-5 by bacterial flagellin, and secretion of interleukin (IL)-β [6]. Resultant intestinal inflammation is characterized by fluid secretion and diarrhea. Salmonellae enter macrophages in the submucosal space and Peyer’s patches where it is able to survive and replicate [6]. Components of the cellular immune system that play a role in clearing salmonella from the macrophages include interferon-γ, IL-12, IL-23, and tumor necrosis factor-α [7]. Patients with HIV, disorders of oxidative cellular killing, and sickle cell disease are at higher risk for invasive NTS disease [8–11].

Pulmonary infections associated with non-typhoid Salmonella pneumonia in immunocompetent hosts are rare in the medical literature. A MEDLINE/PubMED (1966 to October 2016) search limited to the English language and humans using the keywords Salmonella Enteritidis AND pneumonia AND/OR immunocompetent revealed four detailed reports of S. Enteritidis pneumonia and are summarized in Table 2. Hall et al. describe a case of a healthy 24-year-old male who developed severe sepsis, bacteremia and possible pneumonia from S. Enteritidis acquired from contaminated food [12]. Two cases summarized by Knight et al. describe S. Enteritidis pneumonia as a complication of Salmonellosis of the GI track with bacteremia [13]. Neither patient had traditional risk factors for disseminated Salmonellosis, except one had prior exposure to undercooked food. Both were newly diagnosed with diabetes during their hospital stay and were discharged alive with treatment on oral ciprofloxacin. Many reports describe extra-intestinal Salmonellosis in patients with known risk factors such as immunosuppression, living in a developing country, or known exposure to contaminated food [14–17]. One series described in a Taiwanese hospital found an association between extra-intestinal salmonellosis (including pneumonia) and older age, diabetes and chronic lung disease [18]. Samonis et al. describe a 72 year old male with a

| Table 2 | Previous reports S. Enteritidis pneumonia in medical literature. |
|---------|------------------------------------------------------------------|
| Patient | Presentation | Immune status/ Risk factors | Microbiology and Antibiotic Susceptibilities | Treatment/Outcome |
| Our case | Septic shock, pneumonia source | Previously healthy. Developmental disability | S. Enteritidis. Susceptible to cephalosporins, fluoroquinolones, sulfamethoxazole/trimethoprim. Resistant to ampicillin, | Empiric treatment with cefepime, convalescent treatment with levofloxacin for a total of 16 days. Discharged after 28 days to acute care rehab with tracheostomy |
| 24 YO male | Back pain, fevers, rigor | None, possible food-borne transmission | S. Enteritidis. Susceptible to ciprofloxacin, ceftiraxone, azithromycin | Gluteal abscess and blood cultures also positive. Received 14d of ceftriaxone followed by 6 weeks oral ciprofloxacin |
| 65 YO male | Diarrhea, cramps, vomiting | Ingested undercooked eggs, cigarette smoker. Undiagnosed diabetes | S. Enteritidis. Susceptibilities not reported | Developed bacteremia, stool cultures positive. Empiric treatment with cefuroxime and erythromycin. Discharged alive on oral ciprofloxacin |
| 59 YO female | Fever, cough | Undiagnosed diabetes | S. Enteritidis. Susceptibilities not reported | Developed bacteremia. Treated with ciprofloxacin, discharged alive. |
| 72 YO male | 10 months post diagnosis of small cell lung cancer; admitted with low grade fever, dyspnea, tachypnea, chest discomfort, and a productive cough with purulent sputum | Lung cancer | S. Enteritidis. Susceptible to ampicillin, ceftazidime, ceftiraxone, cefotaxime, ciprofloxacin, sulfamethoxazole/trimethoprim | Empiric treatment started with sulfamethoxazole/trimethoprim, ceftazidime, and clindamycin; patient deteriorated, transferred to ICU, developed ARDS, and expired after 3 days |
| 26 YO male | 2 day history of fever, non-productive cough, back pain and shortness of breath | Hodgkin’s lymphoma, concurrent chemo-therapy smoker | S. Enteritidis. Susceptible to cotrimoxazole, ceftriaxone, meropenem, chloramphenicol, and ciprofloxacin. Resistant to nalidixic acid and ampicillin. | Empiric treatment with ceftriaxone for 14d, then discharged home with 14 additional days of oral cefixime |
previous diagnosis of small cell lung cancer who succumbed to a pulmonary infection of S. Enteritidis after five days of treatment with sulfamethoxazole/trimethoprim, cefazidime, and clindamycin [19]. The most recent report comes from the Kingdom of Bahrain [20]. The author describes a case of S. Enteritidis pneumonia complicated by encysted empyema in a 26-year-old male with Hodgkin's lymphoma actively receiving chemotherapy. He was dischaged alive with a 14-day course of a third generation cephalosporin.

The species isolated in our patient's case was a common non-typoid serovar belonging to group D1 Enteritidis. The final serotyping of this sample was confirmed by Kentucky state laboratory testing. Other cases have described salmonellosis with delayed identification, serotyping and susceptibility testing of the pathogen, which can lead to worsening outcomes if proper antimicrobial therapy is delayed [20,21]. Other documented serovars isolated from pulmonary sources include Typhimurium, Derby, Virchow, and Rostock, Dingirí and Abony [15,22–26].

Susceptibility testing of our patient's S. Enteritidis isolate revealed resistance to amoxicillin and susceptibilities to sulfamethoxazole/trimethoprim and levofloxacin. Susceptibility to ceftriaxone was confirmed via the E-test. Emerging resistance to sulfamethoxazole/trimethoprim, fluoroquinolones, and some extended-spectrum cephalosporins has previously been documented [27]. Our patient received a 10-day course of levofloxacin after de-escalating from an empiric regimen of cefepime, meropenzidine, and vancomycin and was eventually discharged from the ICU. The few detailed reports available on salmonella pneumonia report difficulties in treatment and antimicrobial durations of at least two weeks [8,19–22,27–30].

The underlying source of the patient's S. Enteritidis pneumonia was ultimately never discovered. Salmonellosis can be caused by contaminated food or handling animals such as reptiles or amphibians in the environments in which they live. Mermin et al. reported a population-based, case-control study with data suggesting that each year ~74,000 Salmonella infections may be associated with reptile and amphibian exposure [31]. The results of this study concluded that patients with reptile and amphibian exposure attributed the highest risk of infection of numerous assessed risk factors commonly thought to cause salmonellosis in people age 21 or less. The significant number of salmonella infections thought to be caused by amphibian or reptile exposure in this study coincides with our belief that aquatic animal exposure could have been a possible source of infection for our patient infected with S. Enteritidis. Our patient's primary daily hobby was fishing, with likely stream and river water exposure. It is unclear if he had direct contact with aquatic animals such as a turtles, as we were not able to directly ask the patient at any time during his ICU stay.

Overall, this case is noteworthy due to the absence of traditional risk factors associated with severe extra-intestinal disease in the lung from salmonellosis, including pharmacologic immune suppression, auto-immune disease, known exposure to pathogen-borne food and living in a developing country [20]. The patient was only 33 years of age, an age not commonly associated with pneumonia, septic shock and multi-organ failure. Additionally, the patient presumably had a functional immune system prior to admission and was not otherwise overtly immunosuppressed. It is questionable whether or not the diagnosis of intellectual disability could have contributed to increasing his risk of contracting the disease. Our patient did have other risk factors such as taking an acid suppressing medication (pantoprazole), and lower socio-economic class [20]. Most other cases of salmonellosis-associated pneumonia have presented in immunocompromised patients or patients with a primary pulmonary disorder such as lung cancer or lupus [8,10,20–22,27–30]. The presumed method of exposure in this case was from an aspiration event, either prior to admission or at the time of intubation at the outside hospital.

**Conclusion**

We report a case of severe S. Enteritidis pneumonia causing septic shock in a patient with a functional immune system who was not otherwise immunosuppressed. Clinicians should be aware of the potential for S. Enteritidis to be a pathogen in the lung, even in patients without traditional risk factors for S. Enteritidis infection.

**References**

[1] Crump JA, Sjolund-karlsson M, Gordon MA, Parry CM. Epidemiology Clinical. Laboratory presentation diagnosis antimicrobial resistance, and antimicrobial management of invasive salmonella infections. Clin Microbiol 2015;28(4):301–37.

[2] Centers for Disease Control and Prevention. Salmonella. Centers for Disease Control and Prevention: 2015 Retrieved from http://www.cdc.gov/salmonella/ accessed 18.03.16.

[3] Centers for Disease Control and Prevention. Braenderup infections linked to nut butter: Clinical Features/Signs and Symptoms. Atlanta, Georgia: U.S. Department of Health and Human Services, CDC; 2014.

[4] Neal RK, Briji SO, Slack RC, Hawkey CJ, Logan RF. Recent treatment with H2 antagonists and antibiotics and gastric surgery as risk factors for Salmonella infection. Br Med J 1994;308(6222):176.

[5] Francis CI, Starnbach MN, Falkow S. Morphological and cytotoxic changes in epithelial cells occur immediately upon interaction with Salmonella typhimurium grown under low-oxygen conditions. Mol Microbiol 1992;6:3077–72.

[6] Pegues DA, Miller SI. Salmonella species. In: Bennett J, Dolin R, Blaser MJ. editors. Mandell Douglas & Bennett’s Principles and Practice of Infectious Diseases. Philadelphia, PA: Elsevier Press; 2015. p. 2559–68.

[7] MacLennan C, Fieschi C, Lamas DA, Picard C, Dorman SE, Sanal O, et al. Interleukin (IL)-12 and IL-23 are key cytokines for immunity against Salmonella in humans. J Infect Dis 2004;190(10):1755–7.

[8] Gordon MA. Salmonella infections in immunocompromised adults. J Infect 1994;32(6):413–22.

[9] Sommert J, Missuff F, Holvoet T, Ithger H, Lorro M, Benkerrou M, et al. Morbidity among traveler with sicker-cell disease visiting tropical areas: an observational study in a French tertiary care centre. Arch Dis Child 2013;98(7):533–6.

[10] Sallesl P, Roig P, Porti A, Navarro V, Ortiz de la Tabla V, Galant J, et al. Pulmonary confection by Salmonella enteritis and Pneumocystis carinii in a patient with the acquired immunodeficiency syndrome. Eur J Clin Microbiol Infect Dis 1997;16(10):773–4.

[11] Casado JL, Navas E, Frutos B, Moreno A, Martín P, Hermida JM, et al. Salmonella lung involvement in patients with HIV infection. Chest 1997;112(5):1197–201.

[12] Liu B, Partridge R, Venkatraman N, Wuselka M. Invasive non-typoidal salmonella infection with multifocal seeding in an immunocompetent host: an emerging disease in the developed world. BMJ Case Rep 2013.

[13] Knight JC, Knight M, Smith MJ. Two cases of pulmonary complications associated with a recently recognised Salmonella enteritidis phage type, 21b, affecting immunocompetent adults. Eur J Clin Microbiol Infect Dis 2005;24(9);725–6.

[14] Mandomando I, Macete E, Siragque B, Morais I, Quinto L, Sacafial J, et al. Invasive non-typoidal salmonella in mozambican children. Trop Med Int Health 2009;14(December (12)):1467–74.

[15] Ikumapayi UN, Antonio M, Sonne-Hansen J, Binye E, Enwere G, Okoko B, et al. Molecular epidemiology of community-acquired invasive non-typoidal Salmonella among children aged 2–29 months in rural Gambia and discovery of a new serovar, Salmonella enterica. J Microbiol Med 2007Nov;56(Part 11):1479–84.

[16] Berk MR, Meyers AM, Cassal W, Botha JR, Myburgh JA. Non-typoidal salmonella infections after renal transplantation. Serious Clin Prog Nephron 1984;37(3):186–9.

[17] Rodríguez M, de Diego I, Martínez N, Rosario Rodicio M, Carmen Mendoza M. Nontyphoidal Salmonella causing focal infections in patients admitted at a Spanish general hospital during an 11-year period (1991–2001). Int J Med Microbiol 2006;296(4–5):211–22.

[18] Chen PL, Chang CM, Wu CJ, Ko NY, Lee NY, Lee HC, et al. Extraintestinal focal infections in adults with nontyphoidal Salmonella bacteremia: predisposing factors and clinical outcome. J Intern Med 2007Jan;261(1):91–100.

[19] Samonis G, Maraki S, Kouroussis C, Mavrodis D, Georgoulas V. Salmonella enterica pneumonia in a patient with lung cancer. J Clin Microbiol 2003;41(12):5820–2.

[20] Saed N. Salmonella pneumonia complicated with encysted empyema in an immunocompromised youth: case report and literature review. J Infect Dev Ctries 2016;10(4):437–44.

[21] Khan KI, Chaudhary BA, Speir WA. Salmonella pneumonia. J Islamic Med Assoc North Am 1983(5).
[22] Jean SS, Tsai MH, Chen WC, Ho SJ, Wu MH, Hsueh PR. Fatal community-acquired pneumonia caused by Legionella pneumophila and fluoroquinolone-resistant Salmonella enterica serotype Choleraesuis bacteraemia. Int J Antimicrob Agents 2009;33(2).

[23] Rodríguez M, de Diego I, Mendoza MC. Extraintestinal salmonellosis in a general hospital (1991 to 1996): relationships between Salmonella genomic groups and clinical presentations. J Clin Microbiol 1998;36(11):3291–6.

[24] Genzen JR, Towle DM, Kravetz JD, Campbell SM. Salmonella typhimurium pulmonary infection in an immunocompetent patient. Conn Med 2008;72 (March (3)):139–42.

[25] Pitiriga V, Dendrinos J, Nikitiadis E, Vrioni G, Tsakris A. First case of lung abscess due to salmonella enterica serovar abony in an immunocompetent adult patient. Case Rep Infect Dis 2016:2016:3159031, doi:http://dx.doi.org/10.1155/2016/3159031 Epub 2016 Jun 26.

[26] Reiss-Levy E, Isaacs F, Tully M, Clark E. Chronic pulmonary infection with Salmonella typhimurium. Med J Aust 1980;2(12):674–5.

[27] Aguado JM, Obeso G, Cabañillas JJ, Fernandez-Guerrero M, Ales J. Pleuropulmonary infections due to nontyphoid strains of Salmonella. Arch Intern Med 1990;150:54–6.

[28] Woo JW, Tam JK, Chan DS, Wang S, Ying LS. Uncovering what lies beneath a Salmonella enterica empyema. BMJ Case Rep 2015:2.

[29] Gerona JG, Navarra SV. Salmonella infections in patients with systemic lupus erythematosus: a case series. Int J Rheumatic Dis 2009;12(4):319–23.

[30] Ghadage DP, Bal AM. Pneumonia due to an unusual serotype of Salmonella. Indian J Chest Dis Allied Sci 2003;45(1):75–7.

[31] Mermin J, Hutwagner L, Vugia D, Shallow S, Daily P, Bender J, et al. Emerging infections program FoodNet working group reptiles, amphibians, and human salmonella infection: a population-based, case-control study. Clin Infect Dis 2004;38(3):5253–61.